Financial Characteristics of Outcomes-Based Agreements: What Do Canadian Public Payers and Pharmaceutical Manufacturers Prefer?

Mar 1, 2024, 00:00 AM
10.1016/j.jval.2023.12.011
https://www.valueinhealthjournal.com/article/S1098-3015(23)06244-7/fulltext
Section Title : HEALTH POLICY ANALYSIS
Section Order : 340
First Page : 340

Objectives

This study sought to gain insight into the financial characteristics of outcomes-based agreements (OBAs) considered most suitable to Canadian public payers and pharmaceutical manufacturers, and the rationale for their preferences.

Methods

A total of 17 public payers and pharmaceutical manufacturers participated in semistructured qualitative interviews, which assessed their knowledge of OBAs and their preferred financial characteristics.

Results

Payers identified 5 OBA financial models that they considered both acceptable and feasible, in no preferential order: (1) discontinuation of therapy, (2) rebates for nonresponders, (3) free trial period, (4) adjustable pricing, and (5) blended rebate. Payers had a clear preference for short-term OBAs (1 year), whereas both payers and manufacturers agreed OBAs with longer durations (up to 5 years) would be manageable if appropriately designed. Six key success factors to design suitable and acceptable OBA financial models were identified, including the areas of interim reporting, easily measurable health outcomes, trusted data sources, engaging unbiased third-party data experts, harmonizing OBA billing methods, and the inclusion of budget caps.

Conclusions

Manufacturers and payers showed high level of interest in OBAs and a robust understanding of their potential role in supporting timely market access for patients in need, with the caveat that they need to be carefully designed to provide value. Further opportunities for discussion and engagement between public payers and manufacturers are needed to establish how to implement OBAs at a pan-Canadian level and how individual provinces and territories can incorporate them within their existing governance infrastructures.

https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(23)06244-7&doi=10.1016/j.jval.2023.12.011
HEOR Topics :
  • Coverage with Evidence Development & Adaptive Pathways
  • Health Policy & Regulatory
  • Risk-sharing Approaches
  • Study Approaches
  • Surveys & Expert Panels
Tags :
  • financial adjudication
  • financial models
  • implementation
  • market access agreements
  • outcomes-based agreements
Regions :
  • North America